Clinical Trial Update: P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease [Phase 2]

View source ↗

Summary

A Phase 2 open-label study evaluating 2-HPβCD in subjects with diabetic kidney disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Kidney Disease

Drugs mentioned

• 2-HPβCD (2-hydroxypropyl-beta-cyclodextrin)

Snippet

Sponsor: ZyVersa Therapeutics, Inc. | Conditions: Diabetic Kidney Disease | Phase 2 | Status: WITHDRAWN